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RESEARCH ARTICLE
The HPV vaccine: knowledge and attitudes among public health nurses and
general practitioners in Northern Norway after introduction of the vaccine
in the school-based vaccination programme
Karin Nilsena,b, Olaf Gjerløw Aaslandc and Elise Kloumanb
aBodin Surgery, Bodø, Norway; bDepartment of Community Medicine (ISM), UiT The Arctic University of Norway, Tromsø, Norway;
cInstitute for Studies of the Medical Profession (LEFO), Oslo, Norway
ABSTRACT
Objective: To investigate knowledge of and attitudes to human papillomavirus (HPV) infection,
HPV vaccination, cervical cancer, related sources of information and factors associated with will-
ingness to vaccinate one’s own daughter among primary health care (PHC) personnel.
Design: Cross-sectional study.
Setting: PHC.
Subjects: All public health nurses (PHNs) and general practitioners (GPs) in Northern Norway
were invited to answer a structured electronic questionnaire; 31% participated (N¼ 220).
Main outcome measures: Self-reported and actual knowledge, information sources, attitudes
and willingness to vaccinate their (tentative) daughter.
Results: 47% of respondents knew that HPV infection is a necessary cause of cervical cancer.
PHNs had higher self-reported and actual knowledge about HPV vaccination and cervical cancer
than GPs. PHNs used the Norwegian Institute of Public Health’s numerous information sources
on HPV, while GPs had a low user rate. 88% of PHNs and 50% of GPs acquired information from
the pharmaceutical industry. 93% PHNs and 68% of GPs would vaccinate their 12-year-old
daughter. In a multivariate logistic regression analysis, willingness to vaccinate one’s daughter
was positively associated with younger age, being PHN (OR¼ 5.26, 95%CI 1.74–15.94), little con-
cern about vaccine side effects (OR¼ 3.61, 95%CI 1.10–11.81) and disagreement among experts
(OR¼ 7.31, 95%CI 2.73–19.60).
Conclusions: Increased knowledge about HPV infection and vaccination is needed, particularly
among GPs. Those least concerned about side effects and disagreements among experts were
most likely to vaccinate their daughter. These findings are of interest for public health authorities
responsible for the Norwegian vaccination and cervix cancer screening programmes, and pro-
viders of training of PHC personnel.
KEY POINTS
One year after introduction of HPV vaccination among 12-year-old schoolgirls in Norway, a
cross-sectional study in Northern Norway among general practitioners (GPs) and public health
nurses (PHNs) showed that
 barely half of PHC professionals knew the causal relationship between HPV infection and
cervical cancer
 PHNs and GPs had higher self-reported than actual knowledge about HPV vaccination and
cervical cancer
nearly all PHNs and two thirds of GPs wanted to vaccinate their 12-year-old daughter. Those
most concerned about side effects and disagreement among experts were less likely to
vaccinate.
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In 2012, 330 women in Norway got a cervical cancer
diagnosis, and 68 women died from the disease.
Annually, about 3000 women in Norway undergo sur-
gical treatment due to pre-cancerous cervical lesions
[1]. Such uterus-saving procedures can increase the
risk of late miscarriage and preterm delivery in subse-
quent pregnancies [2,3], thus adding to the disease
burden among women infected with the human papil-
lomavirus (HPV). The incidence of cervical cancer varies
across the Nordic countries, with the highest incidence
in Greenland, followed by Denmark, Norway, Iceland,
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Sweden and Finland [4]. A persistent infection with
oncogenic genotypes of HPV is a prerequisite for cer-
vical cancer [4]. The HPV genotypes 16 and 18 account
for approximately 75% of cases of cervical cancer [5].
There were two commercially available HPV vaccines
against these genotypes. The quadrivalent vaccine was
chosen for the Norwegian programme. This vaccine
also counteracts genotypes 6 and 11, causing 86% of
cases of anogenital warts [4,5].
Long-term follow-up studies of the commercially
available vaccines demonstrate their effectiveness in
reducing the incidence of HPV infection with a corre-
sponding reduction in cervical intraepithelial neoplasia
(CIN, grades 2 and 3), and adenocarcinoma in situ
associated with HPV, which are well-documented pre-
dictors of cervical cancer [6–8]. Few serious side effects
have been detected in follow-up studies of the vaccine
[6,8]. Already in 2006 the inclusion of HPV-vaccine in
childhood immunisation programmes was recom-
mended [9]. In 2007, the Norwegian Institute of Public
Health (NIPH) recommended this, and vaccination
started in 2009 for 12-year-old girls [10,11]. In 2008
the European Centre for Disease Prevention and
Control (ECDC) also recommended inclusion of the
HPV vaccine in vaccination programmes [12].
In most Nordic countries, health professionals
who were active in the debate concerning HPV vac-
cination were mostly in favour of the vaccine. In
Norway, there has been disagreement among lead-
ing health professionals, including the editor of the
Journal of the Norwegian Medical Association, about
the safety, efficacy and duration of the HPV vaccine
[4]. In several editorials in 2007/2008 the editor
responded to the health authorities proposals and
the support from an independent governmental
council [13–18], followed by editorials in leading
international medical journals in 2008–09 [19,20].
Her position was that more long-term studies were
needed to collect more data on long-term effects,
side effects and efficacy, since the endpoints in the
trials were precancerous lesions only. She also
argued that replacement by other oncogenic HPV
genotypes could occur when the vaccine reduced
the genotypes 16 and 18 in the population. While
the Norwegian Council for Priority Setting in Health
Care endorsed HPV-vaccination inclusion in the vac-
cination programme [18], the Norwegian College of
General Practice called for a postponement, as did
the Norwegian Biotechnology Advisory Board
[21,22].
In January 2009, the NIPH conducted a nationwide
telephone survey on knowledge and attitudes among
PHNs and GPs on topics related to HPV vaccination to
explore the need for updating among key vaccination
personnel in order to provide proper training before
the HPV-vaccination programme commenced. The
respondents generally held a positive view on HPV
vaccination, but the survey revealed that the PHC pro-
fessionals needed more knowledge about the vaccine,
HPV infection and cervical cancer [23]. During spring
2009, the NIPH in collaboration with the county chief
medical officers arranged courses nationwide on these
topics, mostly relevant for PHNs, and GPs working in
the school-based health service and as municipal pub-
lic health officers. Vaccinations started with girls born
in 1997, and 70% of these girls have received the first
dose, and 67% all three doses, but vaccination cover-
age has steadily increased up to approximately 80%
[24,25]. Other vaccines in the school-based programme
show coverage>90% [4].
In the light of professional controversy and lower
HPV vaccination rates among schoolgirls, the aim of
this study was to identify the extent of knowledge
about and the attitudes towards the HPV vaccine
among PHNs and GPs in order to identify related infor-
mation sources and barriers to uptake; and to stimu-
late further education of the professions on this issue.
Materials and methods
The eligible group consisted of 307 PHNs and 448 GPs
in Nordland, Troms and Finnmark counties, i.e. all pub-
lic health nurses and GPs in Northern Norway. The
membership list of the Norwegian Medical Association
provided the email addresses of all the GPs, while the
northern counties representatives of the Association of
Public Health Nurses provided the email addresses of
the PHNs.
Electronic questionnaires (Questback) were sent by
email in December 2010, with four reminders. Both
PHNs and GPs got the same questions concerning
knowledge and attitudes to HPV infection, vaccination,
and cervical cancer, derived from the NIPH pre-vaccin-
ation survey of PHC professionals [23] New questions
on information sources and willingness to vaccinate
one’s own 12-year-old daughter were added. GPs were
also asked on willingness to vaccinate an older daugh-
ter aged 13–17 years and same-age patients on
request.
Responses on self-reported knowledge and atti-
tudes questions (Tables 1 and 3) were originally given
on a five-point scale from very low/strongly disagree
(value 1) to very high/strongly agree (value 5) or ‘don’t
know’. The Questback form did not allow participants
to continue, unless they had answered the questions







































presented in Tables 1–4. The self-reported knowledge
and attitude responses were dichotomized into high/
clearly agreement responses (values 4 and 5) coded as
'yes' (1), versus all other responses (i.e. values 1–3 and
‘don't know’) coded as zero (0), Actual knowledge
questions were assessed with pre-coded response
alternatives (Table 2) and were coded as ‘true’ (1) ver-
sus ‘false/don’t know’ (0). ‘Don’t know’ responses were
few on the self-reported knowledge questions (2–5 on
each) and on attitude questions (mostly in the range
0–3). The actual knowledge response had several
‘don’t know responses’, mostly two-digit responses on
each question (range 10–36).
We were primarily interested in identifying associa-
tions between a positive attitude towards the HPV vac-
cine and possible correlates. A willingness to vaccinate
your own (tentative) 12-year-old daughter, interpreted
as a positive attitude to HPV-vaccination, was selected
as the dependent variable in the logistic regression
analyses. The pre-coded responses were coded as ‘yes’
(1) and ‘no/don’t know’ as zero (0): 12.7% answered
‘don’t know’, 18.2% of GPs and 6.1% of PHNs. In the
logistic regression analyses, the GPs and PHNs were
collapsed into one group of PHC personnel.
Three items on self-reported knowledge (Table 1)
were included as independent variables. The selection
of other independent variables was done ‘a priori’,
based on what the team considered the most relevant
knowledge, and the most important attitudes reflect-
ing the public debate, i.e. the three first questions in
Table 2, and the four first questions in Table 3. All the
four independent attitude variables were based on
‘negative statements’, i.e. ‘concerned/unsure/worried’
regarding the HPV vaccine. Responses agreeing with
the negative statements (values 4–5) and ‘don’t know’
responses were coded as zero (0), while responses that
disagreed/were indifferent with the negative attitudes
towards the vaccine (values 1–3) were coded as one
(1). The other independent variables on self-reported
knowledge (Table 1) were coded in the same way; low
self-reported knowledge (values 1–2) and ‘don’t know’
as zero (0), and high/middle self-reported knowledge
(values 3–5) as one (1) . The exact knowledge answers
(Table 2) kept the same coding as before, i.e. ‘true’ vs.
‘false/don’t know’.
Differences between GPs and PHNs were tested by
the chi-square test and Fishers Exact Test (when
applicable), and 95% confidence intervals (CI) for pro-
portions are provided. All variables with a bivariate sig-
nificant correlation with the dependent variable were
included in the multivariate analysis (Table 4).
SPSS version 19 was used for data processing and
analyses.
Results
The overall response rate was 31% (220/709): 33%
(99/299) for PHNs and 30% (121/410) for GPs. Eight
nurses and 38 doctors replied that they could not
access the form, had left their job or were on leave
and therefore unavailable. No significant differences
were found in age distribution between the respond-
ents and all GPs and PHNs in Northern Norway (Figure 1).
55(46–64)% of the doctors were GP specialists, compared
to 49(44–54)% of all GPs in Northern Norway, while
49(42–58)% were women, compared to 42(37–47)% of
the GPs in the region .
Knowledge and attitudes among GPs and PHNs
PHNs had higher self-reported knowledge of the HPV
infection, the extent of cervical cancer and HPV vaccin-
ation than GPs (Table 1). GPs were more knowledge-
able of the causal relationship between HPV and
cervical cancer than PHN, however, in both groups the
knowledge was relatively low. PHNs knew more about
HPV infection, cervical cancer and the vaccine than
GPs on five of seven knowledge questions (Table 2).
Self-reported knowledge was considerably higher than
actual knowledge among both professionals (Tables 1
and 2). Attitudes among GPs and PHNs concerning
HPV infection, cervical cancer and the HPV vaccine are
presented in Table 3. More PHNs than GPs believed
that the HPV vaccine was important in preventing
genital warts and the development of cervical cancer.
However, on all the 12 attitude questions, GPs were
more worried than PHNs about the HPV vaccine’s pos-
sible negative effects, and less optimistic about its
potential benefits, although only significantly on half
of the questions.
None PHNs and 2(0–5)% GPs worried that HPV-
vaccination would cause earlier sex debut, while
3(0–6)% PHNs and 4(1–8)% GPs worried about more
unprotected sex (data not shown).
Information sources used by PHC personnel
PHNs and GPs used available information sources on
HPV vaccine differently (Table 4). PHNs overwhelm-
ingly acquired knowledge about the HPV vaccine from
the NIPH [26, 10], compared to one third or less of
GPs. GPs acquired knowledge mainly from the maga-
zine Dagens Medisin, 80 (73–87) %, the Journal of the
Norwegian Medical Association, 79 (72–86) % and the
Norwegian Electronic Medical Handbook NEL, 50
(41–59) %. While nearly two thirds of PHNs attended
the nationwide courses before initiation of vaccination
programme, few GPs did so. Nearly nine of ten PHNs







































compared to half of the GP used information material
provided by the pharmaceutical industry. Few GPs
compared to one fifth of PHCN attended courses,
while one fifth of both groups participated in evening
meetings arranged by the pharmaceutical industry
If you had a daughter, would you vaccinate her?
If they had a 12-year-old daughter, 92(87–97) % of
PHNs and 68(60–79) % of GPs would vaccinate her
(p¼ 0.000). The relationship between willingness to
vaccinate one’s daughter and selected knowledge
and attitude questions was examined by logistic
regression modelling (Table 5). Both univariate and
multivariate analyses show that PHNs were more
positive than GPs towards vaccination, as were
younger compared with older respondents. Those
reporting precise knowledge on the percentage of
cervical cancer caused by the genotypes HPV 16
and 18, and those least concerned about side effects
Table 1. Proportion (%) of GPs and public health nurses in Northern Norway with self-reported high knowledge of HPV infection,
vaccine and cervical cancer (95% CI).a
GPs (n¼ 121) % Public health nurses (n¼ 99) % pb
How much knowledge do you think you have about HPV and cervical cancer?c 84 (77–91) 97 (93–100) <0.001
How much knowledge do you think you have about the extent of cervical cancer?c 61 (51–70) 81 (73–89) <0.001
How much knowledge do you think you have about the HPV vaccine?c 64 (55–73) 99 (97–101) <0.001
aOne year after the introduction of the HPV vaccine in the vaccination programme.
bSignificant differences between GPs and PHN in bold, p value based on the Chi square test.
cUsed as independent variables in logistic regression model(s).
Table 2. Knowledge of HPV infection, vaccine and cervical cancer among GPs and public health nurses in Northern Norway:
Proportions (%) giving correct answer to each question (95% CI).a
GPs (n¼ 121) %
Public health
nurses (n¼ 99) % pb Correct answer
What percentage of cervical cancer is
caused by HPV?d
55 (45–65) 37 (28–46) 0.008 100%c
What is the lifetime risk of a sexually
active person getting HPV infectiond
26 (17–35) 35 (27–44) 0.117 70%
What percentage of cervical cancer do
the genotypes HPV16 and 18 cause?d
44 (35–53) 58 (48–68) 0.042 70%
How many cases of cervical cancer do
you think we have in Norway per
year?
43 (33–53) 64 (56–73) 0.002 300
How many operations for precancerous
lesions are performed in Norway per
year?
32 (23–39) 56 (46–66) <0.000 3000
Which vaccine was chosen for the
programme in Norway?
33 (25–41) 86 (79–93) <0.000 4-valent, against genotypes 6,
11, 16 and 18
What is the price of one dose of this
vaccine?
41 (32–50) 68 (59–77) <0.000 NOK 1200
aOne year after the introduction of the HPV vaccine in the vaccination programme.
bSignificant differences between GPs and PHN in bold, p value based on the Chi square test.
c90–100% accepted as correct answer.
dUsed as independent variables in logistic regression model(s).
Table 3. Attitudes towards HPV infection, vaccine and cervical cancer among GPs and public health nurses in Northern Norway:
Proportion (%) agreeing with the following statements (95% CI).a
GPs (n¼ 121) %
Public health
nurses (n¼ 99) % pb
I am very concerned about possible side effects in the long termd 13 (7–19) 9 (3–15) 0.337
I am very unsure about whether the vaccine is effective enough against cancerd 21 (14–28) 17 (10–24) 0.512
I am worried that the vaccine may make the screening programme less populard 22 (15–29) 14 (7–21) 0.160
I am concerned because there is much disagreement among experts about the vaccined 24 (16–32) 15 (8–22) 0.104
I do not believe the effect of the vaccine lasts long enough 9 (4–14) 6 (1–11) 0.402
The vaccine is important to prevent women needing operations to avoid cervical cancer 58 (49–67) 72 (63–81) 0.033
I do not think HPV or cervical cancer is such a big problem that we need the HPV vaccine 11 (5–17) 6 (1–11) 0.219
The vaccine is important to prevent the development of cervical cancer 79 (72–86) 96 (92–100) <0.000
The screening programme for cervical cancer is so good that the HPV vaccine is unnecessary 12 (6–18) 2 (0–5) 0.008c
Cervical cancer is a public health problem 40 (31–49) 56 (46–66) 0.019
Precancerous lesions is a public health problem 50 (41–59) 67 (58–76) 0.015
The vaccine is important for preventing genital warts 31 (23–39) 75 (66–84) <0.000
aOne year after the inclusion of the HPV vaccine in the childhood vaccination programme.
bSignificant differences between GPs and PHN in bold, p value based on Chi square test and.
cFisher’s Exact Test.
dUsed as independent variables in logistic regression model(s).







































and disagreement among experts were most likely
to vaccinate their daughter.
95(90–100) % of the PHNs who themselves adminis-
tered the HPV vaccination would vaccinate their 12-
year-old daughter, as well as 80(70–90) % of GPs
under 40 years. 54 (45–63) % of GPs would vaccinate
an older daughter aged 13–17 years; 80 (73–87) %
would recommend the vaccine for the same age-
group to patients requesting information.
An association existed between the 90% of PHNs
regularly viewing the NIPH website (Table 4) and will-
ingness to vaccinate their 12-year-old daughter
(p¼ 0.007). Such association did not exist in the one
third of GPs regularly viewing the website (p¼ 0.712)
The PHC personnel had great confidence in the NIPH,
and this confidence was associated with a positive atti-
tude to vaccination; 92(87–97) % of PHNs (p< 0.001)
and 84 (77–91) % of GPs (p¼ 0.009).
Discussion
Self-reported and actual knowledge of HPV infection,
cervical cancer and their interrelationship has
improved among PHNs and GPs in Northern Norway
compared with a national survey before the HPV
vaccination programme started [23]. Interestingly, self--
reported knowledge was much higher than actual
knowledge in both professional groups, and barely half
of these PHC professionals knew that HPV infection
causes cervical cancer. This was, however, the only
knowledge question where GPs answered correctly
more often than PHNs. Attitudes to HPV vaccination
among the GPs and PHNs are predominantly positive.
Concern about expert disagreement and side effects
are the attitudes most strongly associated with low will-
ingness to vaccinate one’s 12-year-old daughter. While
more than nine in ten PHNs wanted to vaccinate their
daughter, two of three GPs shared that view.
Strengths and weaknesses of the study
The age distribution among all respondents, the pro-
portion of women and GP specialists did not differ
from GPs and PHNs in Northern Norway. We therefore
consider our sample fairly representative of the PHC
personnel, and thus providing trustworthy study
results useful for public health authorities responsible
for the Norwegian HPV prevention programmes and
Table 4. Information sources on the HPV-vaccine used by public health nurses (PHN) and GPs in Northern Norway in proportions
(%) and 95% CI.a
GPs (n¼ 121) % Public health nurses (n¼ 99) % pb
NIPH Booklet (ref. [26]) 30 (22–38) 98 (95–100) 0.000
NIPH Rapport (ref. [10)) 30 (22–38) 85 (79–91) 0.000
NIPH webside 33 (25–41) 90 (84–96) 0.000
Nationwide courses before initiation of vaccination programme 3 (0–6) 63 (53–73) 0.000c
Pharmaceutical Industry, information brochuresd 50 (41–59) 88 (82–94) 0.000
Pharma courses 6 (2–10) 19 (11–27) 0.002
Pharma evening meetings 22 (15–29) 22 (14–30) 0.896
aOne year after the inclusion of the HPV vaccine in the childhood vaccination programme.
bSignificant differences between GPs and PHN in bold, p value based on Chi square test.
cFisher’s Exact Test.
dInformation brochures on HPV vaccine sent by post to all public health nurses and GPs from pharmaceutical industry.
Table 5. Knowledge and attitudesa associated with willingness to HPV vaccinate their own 12-year-old
daughter among 220 Northern Norwegian GPs and public health nurses.b
Crude OR (95% CI) Multivariate OR (95% CI)
Age (in 10-year age groups) 0.73 (0.53–0.99) 0.62 (0.40–0.95)
Profession (nurses vs. GPs) 5.40 (2.39–12.25) 5.26 (1.74–15.94)
High self-reported knowledge of HPV vaccine 2.23 (1.08–4.63) 2.23 (0.78–6.33)
Correct, lifetime risk of HPV infection 2.46 (1.08–5.60) 2.24 (0.78–6.45)
Correct, percent of ca. cervix due to HPV 16/18 2.94 (1.45–5.88) 2.89 (1.18–7.05)
Not concerned about side effects 8.35 (3.56–19.58) 3.61 (1.10–11.87)
Sure of good enough effect 3.06 (1.49–6.31) 2.12 (0.79–5.67)
Not worried re. screening popularity 2.60 (1.78–5.28) 1.37 (0.52–3.59)
Not concerned on experts disagreement 11.95 (5.63–25.35) 7.31 (2.73–19)
All independent variables significantly associated with the dependent variable in crude log. regression analyses were
included in the multivariate analysis and are shown in the table.
aIndependent variables in crude log. regression analyses included age, profession, the three self-reported variables (pre-
sented in Table 1) and three selected actual knowledge variables (top three variables in Table 2) and four selected attitude
variables (top four variables in Table 3). All independent variables selected from Table 1–3 are marked in these tables
withd.
bSignificant differences presented in bold.







































providers of training of PHC personnel. However,
when only one third of the eligible professionals par-
ticipate, selection bias cannot be ruled out. Much
debate about the vaccine may have encouraged those
among GPs holding a less positive view on HPV vac-
cination to participate. That one third of GPs did not
have a clear positive attitude to vaccinate their daugh-
ter may support this view. Implementing the vaccin-
ation programme in Norway is among prioritized
responsibilities of PHNs. This may have discouraged
participation among PHNs who were not in favour of
the vaccine, which obviously may be a very difficult
position to hold for a PHN. If this is the case, such
selection bias can explain some of the differences
among GPs and PHNs.
One limitation of the study is the low response rate.
Some GPs will always be absent from their practice for
specialist training, maternity and sick leave, which also
may be the case for PHNs. However, response rates of
25–50% among doctors are not uncommon [27–31],
may vary in different work situations and be lower in
online than postal surveys [30]. Possible causes are
time pressures, lack of financial incentive, many similar
requests, little feedback on findings and like ours, long
questionnaires [27].
Knowledge, attitudes and related information
sources among PHC professionals
Four of five GPs obtained information about the vac-
cine from the Journal of the Norwegian Medical
Association and the Norwegian magazine Dagens
Medisin. GPs’ main information sources thus were the
platforms where debates and critical views on the HPV
vaccine were present. The NIPH is a national expert
body on vaccines. Fewer GPs than PHNs used the
HPV-related numerous NIPH information sources,
which is natural since PHNs carry out the vaccination
programme initiated by the NIPH [10,24–26]. GPs'
main task is to provide individual advice on HPV vac-
cination for their patients, but they also carry out the
cervix cancer screening programme. Therefore, it is
not out of place to expect that GPs are knowledgeable
on topics related to prevention of cervix and other
HPV-related cancers. An obvious barrier to uptake of
information on HPV-related issues among GPs, is their
low user rate of the NIPH information sources.
Even though 84% of GPs in our study had great
confidence in NIPH, the minority may also have lost
trust the NIPH after the influenza pandemic which
coincided with the initiation of the HPV vaccination
programme. Handling of the pandemic influenza out-
break put the Norwegian PHC personnel under heavy
strain [32]. In Northern Norway, the district medical
officers in charge of infectious disease control and
doctors working in the school health services, usually
also do clinical work as GPs. The capacity among GPs
to acquire new knowledge on HPV vaccination, well
carried out by the PHNs, may thus have been limited
at programme start. GPs may also have been more
attentive to attitudes held by the Norwegian College
of General Practice, and the editor of the Journal of
the Norwegian Medical Association calling for a post-
ponement of the programme [21,13–17,19].
Nine out of ten PHNs used the pharmaceutical
industry as a source of information, compared to half
of the GPs, which indicates that the industry may have
identified PHNs as an important target group for its
marketing. The manufacturer of the vaccine chosen for
the Norwegian programme has been criticised for its
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Figure 1. Age distribution of respondents (%) compared with all the nurses and GPs in Northern Norway.







































marketing methods in the US [33]. In the public
debate in Denmark and in Norway, the manufactures
were criticised for under-reporting the risks and over-
reporting the benefits of HPV vaccination, and for hid-
den competing interests among high-ranking health
officials and expects [4]. However, the PHNs were
more knowledgeable than the GPs on nearly all issues
relating to HPV vaccination. This is not surprising,
because GPs are less involved in the HPV vaccination
programme, if they do not work in school health serv-
ices. Norwegian PHC professionals did no worry that
HPV vaccination would influence sexual behaviour.
A large study on sexual behaviour among HPV vacci-
nated and non-vaccinated young Nordic women sup-
port that view [34].
Would you vaccinate your daughter?
The percentage of GPs who would vaccinate a 12-
year-old daughter (68%) was roughly equal to that of
girls completing first round of vaccination (67%) [24],
hence GPs would vaccinate their children like the gen-
eral population. GPs and PHNs who had confidence in
the NIPH, were more positive to vaccinate their daugh-
ter than those who did not share that view. A Swiss
study shows that many doctors disregard the official
vaccination programme for their children although
complying with it for their patients [35]. This concurs
with GPs being more likely to vaccinate patients than
their own daughters in our study. However, GPs are
more willing to vaccinate their 12-year-old daughter
within the programme, than a slightly older daughter
outside the programme (68% vs. 54%). Older doctors
are more sceptical to the vaccine, perhaps because
the issue of vaccinating one’s own daughter seems
less relevant for this age group.
Comparison of knowledge and attitudes among
GPs from different countries
Australian GPs had moderate knowledge of HPV infec-
tion and vaccination one year after initiation of the
Australian vaccination programme for 13-year-old girls;
Younger and female GPs had greater knowledge of
HPV than older GPs [31]. Italian GPs reported a lack of
knowledge on HPV infection and vaccination, with no
difference in knowledge by age, gender, level of edu-
cation or region of origin [36]. Norwegian GPs
reported low to moderate knowledge, no gender dif-
ference and no greater knowledge among younger
GPs. 77% of Australian GPs had no concerns about the
safety of the vaccine, interpreted as being slightly
more positive than Norwegian GPs, even though
questions were not directly comparable. Surprisingly,
GPs from Norway, Australia and Italy, have in common
weak knowledge of HPV infection and vaccination.
This is a challenge for public health authorities, and
GPs themselves in providing individual advice to
parents and patients.
Conclusions
Barely half of PHC professionals knew that HPV
infection causes cervical cancer, PHNs carry out the
vaccination programme and had higher actual and
self-reported knowledge than GPs who mostly carry
out the cervix cancer screening programme and pro-
vide individual advice to parents and patients on HPV
vaccination. Contrary to half of the GPs, most PHNs
acquired information from the pharmaceutical indus-
try. Both professional groups had high confidence in
NIPH. PHNs used NIPH’s numerous information source
on HPV, while GPs had a low user rate, which may
appear as a barrier to better knowledge among GPs.
More than nine in ten PHNs wanted to vaccinate their
12-year-old daughter compared to two of three GPs. A
positive attitude towards HPV vaccination was strongly
associated with younger age, being a PHN, and not
concerned about side effects or expert disagreement.
The study results can be utilized to update curricula
for medical and nurse students, and to guide post-
graduate training of PHC personnel by the NIPH and
the Cancer Registry of Norway.
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